{"abstract": "Questcor Pharmaceuticals has been criticized for steadily raising the price of its most valuable product, but that aggressive pricing strategy appears to have paid off for the drug maker.", "web_url": "https://dealbook.nytimes.com/2014/04/07/mallinckrodt-to-buy-californias-questcor-for-5-6-billion/", "snippet": "Questcor Pharmaceuticals has been criticized for steadily raising the price of its most valuable product, but that aggressive pricing strategy appears to have paid off for the drug maker.", "lead_paragraph": "Updated, 8:22 p.m. | Questcor Pharmaceuticals has been criticized for steadily raising the price of its most valuable product \u2014 a 60-year-old immune system drug \u2014 to more than $28,000 a vial from $40 in just a decade. Critics have said the price increases were excessive, and short-sellers have predicted the company\u2019s business and stock price would collapse. ", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/08/business/Drug/Drug-jumbo.jpg", "height": 589, "width": 589, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/08/business/Drug/Drug-superJumbo.jpg", "height": 589, "width": 589, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/08/business/Drug/Drug-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/04/08/business/Drug/Drug-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/08/business/Drug/Drug-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Mallinckrodt Pharmaceuticals to Buy Questcor for $5.6 Billion", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Acthar (Drug)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Autoimmune Diseases", "rank": 2, "major": "N"}, {"name": "subject", "value": "Boards of Directors", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": 5, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 6, "major": "N"}, {"name": "subject", "value": "Stocks and Bonds", "rank": 7, "major": "N"}, {"name": "persons", "value": "Bailey, Don M", "rank": 8, "major": "N"}, {"name": "organizations", "value": "Barclays PLC", "rank": 9, "major": "N"}, {"name": "organizations", "value": "Cadence Pharmaceuticals Inc", "rank": 10, "major": "N"}, {"name": "organizations", "value": "Centerview Partners", "rank": 11, "major": "N"}, {"name": "organizations", "value": "Chronic Disease Fund", "rank": 12, "major": "N"}, {"name": "organizations", "value": "Justice Department", "rank": 13, "major": "N"}, {"name": "organizations", "value": "Latham & Watkins LLP", "rank": 14, "major": "N"}, {"name": "organizations", "value": "Mallinckrodt Pharmaceuticals", "rank": 15, "major": "N"}, {"name": "organizations", "value": "Novartis AG", "rank": 16, "major": "N"}, {"name": "organizations", "value": "Questcor Pharmaceuticals Incorporated", "rank": 17, "major": "N"}, {"name": "organizations", "value": "Securities and Exchange Commission", "rank": 18, "major": "N"}, {"name": "organizations", "value": "WACHTELL LIPTON ROSEN & KATZ", "rank": 19, "major": "N"}, {"name": "glocations", "value": "ANAHEIM (CALIF)", "rank": 20, "major": "N"}, {"name": "glocations", "value": "California", "rank": 21, "major": "N"}, {"name": "glocations", "value": "Dublin (Ireland)", "rank": 22, "major": "N"}, {"name": "glocations", "value": "San Diego (Calif)", "rank": 23, "major": "N"}], "pub_date": "2014-04-07T12:33:02+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack and Chad Bray", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c5ff02a5-e175-5e35-8e6a-5e7194cdbf00", "word_count": 719, "uri": "nyt://article/c5ff02a5-e175-5e35-8e6a-5e7194cdbf00"}